Latest Breaking News On - Stephanie carrington - Page 7 : comparemela.com

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a m ET - Aquestive Therapeutics (NASDAQ:AQST)

WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'

Stephanie carringtonExchange commissionCompany or aquestiveAquestive therapeutics incPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reportsAquestive therapeutics

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for

REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today

United statesStephanie carringtonSusan stewartEuropean medicines agencySecurities exchangeEuropean unionRezolute incPriority medicinesChief regulatory officerOrphan drug designationPediatric rare disease designationSecurities actSecurities exchange actPrivate securities litigation reform actRisk factorsAnnual report

Rezolute Announces Further Evidence of RZ358 s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute Announces Further Evidence of RZ358 s Efficacy in Tumor-Mediated Hyperinsulinism
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesStephanie carringtonRezolute incEuropean unionCompany phaseSecurities exchangeAnnounces further evidenceNew england journalChief medical officerOrphan drug designationPediatric rare disease designationSecurities actSecurities exchange actPrivate securities litigation reform actRisk factorsAnnual report

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesWilliam caoMarvin tangJessica laubStephanie carringtonAmerican society for clinical oncologyGracell biotechnologies incExchange commissionFierce life sciences innovationEuropean hematology associationBiotechnologies doses first patientRefractory multipleChief executive officerAmerican societyClinical oncologyBiotech innovation

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U S Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesMarvin tang jessica laubWilliam caoStephanie carringtonAmerican society for clinical oncologyExchange commissionGracell biotechnologies incEuropean hematology associationFierce life sciences innovationGracell biotechnologiesChief executive officerAmerican societyClinical oncologyBiotech innovationLife sciences innovation awardsPrivate securities litigation reform act